Home
Resources
Diseases
Training
SYSVAC
About
Registry
E-learning courses
News
Events
Network
Vision and Mission
Steering Committee
Map
Meetings
Join us
Home
Resources
Resources
Selected
Hepatitis B
Human papillomavirus (HPV)
Rubella
SAGE documentation
Evidence to recommendation table
Clear all
Type of publications
SAGE documentation
(7)
Topics
Evidence to recommendation table
(7)
Regions
Countries
Diseases
Hepatitis B
(2)
Human papillomavirus (HPV)
(3)
Rubella
(2)
COVID-19
(2)
Dengue
(2)
Diphtheria
(1)
Influenza
(1)
Malaria
(2)
Measles
(2)
Mpox // Monkeypox
(1)
Pertussis
(1)
Pneumococcal disease
(2)
Rabies
(2)
Tuberculosis
(6)
Typhoid
(1)
Publication date
2020
(1)
2017
(5)
Target population
Available to download in languages
English (EN)
(7)
7 results found
2020
∙
SAGE
Which combined rubella and congenital rubella syndrome (CRS) control and elimination strategies should be recommended?
2017
∙
SAGE
Evidence to recommendation table (duration)
2017
∙
SAGE
Evidence to recommendation table (birth dose)
2017
∙
SAGE
In 9 to 15-year old females, is 9-valent human papillomavirus vaccine (HPV) vaccine superior to 4-valent or 2-valent HPV vaccines?
2017
∙
SAGE
What is the incremental effectiveness and cost-effectiveness of vaccinating multiple age cohorts versus a single age cohort in high income countries (HIC) and low and middle income countries (LMIC)?
2017
∙
SAGE
What is the public health impact on cervical cancer of administering HPV vaccine to 9 to 15-year old females and males versus to 9 to 15-year old females?
SAGE
Does the evidence support co-administration of measles-rubella (MR)/measles-mumps-rubella (MMR) and yellow fever (YF) vaccines?
Home
Resources
Diseases
Training
SYSVAC
News
Events
Network
Sign in / Register